Krystal Biotech
KRYS
13 hedge funds and large institutions have $31.3M invested in Krystal Biotech in 2017 Q3 according to their latest regulatory filings, with 13 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
32.6% more ownership
Funds ownership: 0% → 32.6% (+33%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.1M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$7.06M |
| 3 |
HCM
Highbridge Capital Management
New York
|
+$3.02M |
| 4 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$3.02M |
| 5 |
TCP
Tourbillon Capital Partners
New York
|
+$2.52M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Fidelity Investments
Boston,
Massachusetts
| $12M | +$12.1M | +1,200,000 | New |
|
|
RCM
2
RA Capital Management
Boston,
Massachusetts
| $6.98M | +$7.06M | +700,000 | New |
|
|
HCM
3
Highbridge Capital Management
New York
| $2.99M | +$3.02M | +300,000 | New |
|
|
KCM
4
Knoll Capital Management
Miami,
Florida
| $2.99M | +$3.02M | +300,000 | New |
|
|
TCP
5
Tourbillon Capital Partners
New York
| $2.49M | +$2.52M | +250,000 | New |
|
|
BBA
6
Baker Bros. Advisors
New York
| $1.99M | +$2.02M | +200,000 | New |
|
|
AG
7
Artal Group
Luxembourg
| $997K | +$1.01M | +100,000 | New |
|
|
SM
8
Sabby Management
Miami Beach,
Florida
| $534K | +$540K | +53,558 | New |
|
9
Goldman Sachs
New York
| $197K | +$200K | +19,800 | New |
|
|
TSS
10
Two Sigma Securities
New York
| $137K | +$139K | +13,786 | New |
|
11
UBS Group
Zurich,
Switzerland
| $26K | +$25.8K | +2,562 | New |
|
|
FMA
12
FNY Managed Accounts
New York
| $23K | +$24.2K | +2,400 | New |
|
|
CCA
13
Catalyst Capital Advisors
Huntington,
New York
| $5K | +$4.69K | +465 | New |
|
KRYS Hedge Fund Activity: Q3 2017 in Review
13 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q3 2017, worth a combined $31.3M.
Buyers outnumbered sellers: 13 funds opened new KRYS positions and 0 closed out — a net gain of 13 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $12.1M.
- 13 institutional investors held Krystal Biotech (KRYS) as of Q3 2017, up from 0 in Q2 2017.
- Funds reported $31.3M of Krystal Biotech stock for Q3 2017.
- 13 funds opened new Krystal Biotech positions in Q3 2017 and 0 closed out, a net change of +13 holders.
- The largest Krystal Biotech buyer in Q3 2017 was Fidelity Investments, an estimated $12.1M added.
Based on aggregated 13F filings for Q3 2017.